3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
48
Gastrointestinal
5
Tumor-Agnostic
4
Lymphoid
3
Gynecologic
3
Thoracic
2
Plasma cell
2
Other hematologic neoplasm
2
Head & Neck
2
Sarcoma
1
Genitourinary
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
65
Nivolumab
59
Ipilimumab
33
Cyclophosphamide
23
Specimen Handling
16
Magnetic Resonance Spectroscopy
15
Biopsy
15
relatlimab
13
fludarabine
13
cemiplimab
13
Opdualag
12
Blood Specimen Collection
11
binimetinib
10
aldesleukin
9
Radiosurgery
9
Interleukin-2
9
encorafenib
8
atezolizumab
7
Immunotherapy
7
tebentafusp
6
mogamulizumab
6
fludarabine phosphate
6
Temozolomide
6
Surgical Procedures, Operative
6
Paclitaxel
6
Immunoglobulin G
6
CTLA-4 Antigen
6
Aminolevulinic Acid
6
Radiotherapy
5
Disulfides
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
pertuzumab
×
Dermatologic
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled